Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score

Background: Immunohistological assessment of Ki 67 expression is less expensive than Oncotype Dx, which is currently used to identify patients with lymph node-negative breast cancer, who will benefit from adjuvant chemotherapy. Methods: The relationship of immunohistologically measured Ki 67 to Onco...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2011-10, Vol.105 (9), p.1342-1345
Main Authors: Sahebjam, S, Aloyz, R, Pilavdzic, D, Brisson, M-L, Ferrario, C, Bouganim, N, Cohen, V, Miller, W H, Panasci, L C
Format: Article
Language:English
Subjects:
631/45/880/1257
692/699/67/1347
692/699/67/1857
692/700/139/1512
Biological and medical sciences
Biomarkers, Tumor - metabolism
Biomedical and Life Sciences
Biomedicine
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - genetics
Breast Neoplasms - metabolism
Cancer
Cancer Research
Chemotherapy
Chemotherapy, Adjuvant
Drug Resistance
Epidemiology
Female
Gene Expression Profiling
Humans
Ki-67 Antigen - metabolism
Medical sciences
Molecular Medicine
Oncology
Predictive Value of Tests
Prognosis
Real-Time Polymerase Chain Reaction - methods
Recurrence
Short Communication
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Immunohistological assessment of Ki 67 expression is less expensive than Oncotype Dx, which is currently used to identify patients with lymph node-negative breast cancer, who will benefit from adjuvant chemotherapy. Methods: The relationship of immunohistologically measured Ki 67 to Oncotype DX recurrence score (RS) was examined in 53 cases of T1–2 N0 M0 (oestrogen receptor-positive, HER2/neu negative) breast cancer. Results: There was a strong linear correlation between Ki 67 value and the Oncotype Dx RS. All patients in the low Ki 67 group (Ki 67 of ⩽10%) had Oncotype Dx RSs of low or intermediate risk. The vast majority of patients (93.8%) in the high-Ki 67 group (Ki 67⩾25%) had oncotype RSs of high or intermediate risk. Conclusion: Ki 67 proliferation value is a major, but not the sole determinant of Oncotype Dx score.
ISSN:0007-0920
1532-1827
DOI:10.1038/bjc.2011.402